4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (NASDAQ:FDMT), a late-stage biotechnology company, has announced its participation in three major investor conferences in September 2025. The management team will engage in fireside chats and be available for one-on-one meetings at the following events:
- Cantor Global Healthcare Conference on September 4 at 11:30 a.m. ET
- H.C. Wainwright Global Investment Conference on September 9 at 10:00 a.m. ET
- Morgan Stanley Global Healthcare Conference on September 9 at 1:50 p.m. ET
Webcasts of the presentations will be available on the company's investor relations website, with archived recordings accessible for up to one year.
4D Molecular Therapeutics (NASDAQ:FDMT), una società biotecnologica in fase avanzata, ha annunciato la propria partecipazione a tre importanti conferenze per investitori a settembre 2025. Il team dirigente parteciperà a discussioni informali (fireside chats) e sarà disponibile per incontri individuali ai seguenti eventi:
- Cantor Global Healthcare Conference il 4 settembre alle 11:30 ET
- H.C. Wainwright Global Investment Conference il 9 settembre alle 10:00 ET
- Morgan Stanley Global Healthcare Conference il 9 settembre alle 13:50 ET
I webcast delle presentazioni saranno disponibili sul sito investor relations della società, con registrazioni archiviate accessibili per un massimo di un anno.
4D Molecular Therapeutics (NASDAQ:FDMT), una empresa biotecnológica en fase avanzada, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025. El equipo directivo participará en charlas informales (fireside chats) y estará disponible para reuniones individuales en los siguientes eventos:
- Cantor Global Healthcare Conference el 4 de septiembre a las 11:30 a. m. ET
- H.C. Wainwright Global Investment Conference el 9 de septiembre a las 10:00 a. m. ET
- Morgan Stanley Global Healthcare Conference el 9 de septiembre a la 1:50 p. m. ET
Los webcast de las presentaciones estarán disponibles en la web de relaciones con inversores de la compañía, y las grabaciones archivadas podrán consultarse hasta por un año.
4D Molecular Therapeutics (NASDAQ:FDMT)는 후기 단계 바이오테크 기업으로, 2025년 9월에 열리는 세 건의 주요 투자자 컨퍼런스에 참가한다고 발표했습니다. 경영진은 파이어사이드 챗에 참여하고 다음 행사에서 일대일 미팅도 진행할 예정입니다:
- Cantor Global Healthcare Conference 9월 4일 오전 11:30 ET
- H.C. Wainwright Global Investment Conference 9월 9일 오전 10:00 ET
- Morgan Stanley Global Healthcare Conference 9월 9일 오후 1:50 ET
발표의 웹캐스트는 회사의 투자자 관계 웹사이트에서 시청할 수 있으며, 아카이브된 녹화는 최대 1년 동안 제공됩니다.
4D Molecular Therapeutics (NASDAQ:FDMT), une société biotechnologique en phase avancée, a annoncé sa participation à trois grandes conférences pour investisseurs en septembre 2025. L'équipe de direction participera à des discussions informelles (fireside chats) et sera disponible pour des réunions individuelles lors des événements suivants :
- Cantor Global Healthcare Conference le 4 septembre à 11h30 ET
- H.C. Wainwright Global Investment Conference le 9 septembre à 10h00 ET
- Morgan Stanley Global Healthcare Conference le 9 septembre à 13h50 ET
Les webcasts des présentations seront disponibles sur le site relations investisseurs de l'entreprise, avec les enregistrements archivés accessibles pendant un an maximum.
4D Molecular Therapeutics (NASDAQ:FDMT), ein Biotechnologieunternehmen in der Spätphase, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 angekündigt. Das Managementteam wird an Fireside-Chats teilnehmen und für Einzelgespräche bei folgenden Veranstaltungen zur Verfügung stehen:
- Cantor Global Healthcare Conference am 4. September um 11:30 Uhr ET
- H.C. Wainwright Global Investment Conference am 9. September um 10:00 Uhr ET
- Morgan Stanley Global Healthcare Conference am 9. September um 13:50 Uhr ET
Webcasts der Präsentationen werden auf der Investor-Relations-Website des Unternehmens verfügbar sein; archivierte Aufzeichnungen sind bis zu einem Jahr zugänglich.
- None.
- None.
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in September. Members of the management team will also be available for one-on-one meetings.
Cantor Global Healthcare Conference 2025
| Presentation Date: | Thursday, Sept 4, 2025 |
| Presentation Time: | 11:30 a.m. ET |
| Webcast Link: | Webcast |
H.C. Wainwright 27th Annual Global Investment Conference
| Presentation Date: | Tuesday, Sept 9, 2025 |
| Presentation Time: | 10:00 a.m. ET |
| Webcast Link: | Webcast |
Morgan Stanley Annual Global Healthcare Conference
| Presentation Date: | Tuesday, Sept 9, 2025 |
| Presentation Time: | 1:50 p.m. ET |
| Webcast Link: | Webcast |
Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
FAQ
When is 4D Molecular Therapeutics (FDMT) presenting at the Cantor Global Healthcare Conference 2025?
How many investor conferences will FDMT attend in September 2025?
Where can investors access FDMT's conference presentations?
What type of meetings will FDMT management offer at these conferences?
